FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1772185780> ?p ?o ?g. }

• W1772185780 endingPage "25533" @default.
• W1772185780 startingPage "25522" @default.
• W1772185780 abstract "Androgen receptor (AR) plays a role in maintaining telomere stability in prostate cancer cells, as AR inactivation induces telomere dysfunction within 3 h. Since telomere dysfunction in other systems is known to activate ATM (ataxia telangiectasia mutated)-mediated DNA damage response (DDR) signaling pathways, we investigated the role of ATM-mediated DDR signaling in AR-inactivated prostate cancer cells. Indeed, the induction of telomere dysfunction in cells treated with AR-antagonists (Casodex or MDV3100) or AR-siRNA was associated with a dramatic increase in phosphorylation (activation) of ATM and its downstream effector Chk2 and the presenceof phosphorylated ATM at telomeres, indicating activation of DDR signaling at telomeres. Moreover, Casodex washout led to the reversal of telomere dysfunction, indicating repair of damaged telomeres. ATM inhibitor blocked ATM phosphorylation, induced PARP cleavage, abrogated cell cycle checkpoint activation and attenuated the formation of γH2AX foci at telomeres in AR-inactivated cells, suggesting that ATM inhibitor induces apoptosis in AR-inactivated cells by blocking the repair of damaged DNA at telomeres. Finally, colony formation assay revealed a dramatic decrease in the survival of cells co-treated with Casodex and ATM inhibitor as compared with those treated with either Casodex or ATM inhibitor alone. These observations indicate that inhibitors of DDR signaling pathways may offer a unique opportunity to enhance the potency of AR-targeted therapies for the treatment of androgen-sensitive as well as castration-resistant prostate cancer. Androgen receptor (AR) plays a role in maintaining telomere stability in prostate cancer cells, as AR inactivation induces telomere dysfunction within 3 h. Since telomere dysfunction in other systems is known to activate ATM (ataxia telangiectasia mutated)-mediated DNA damage response (DDR) signaling pathways, we investigated the role of ATM-mediated DDR signaling in AR-inactivated prostate cancer cells. Indeed, the induction of telomere dysfunction in cells treated with AR-antagonists (Casodex or MDV3100) or AR-siRNA was associated with a dramatic increase in phosphorylation (activation) of ATM and its downstream effector Chk2 and the presenceof phosphorylated ATM at telomeres, indicating activation of DDR signaling at telomeres. Moreover, Casodex washout led to the reversal of telomere dysfunction, indicating repair of damaged telomeres. ATM inhibitor blocked ATM phosphorylation, induced PARP cleavage, abrogated cell cycle checkpoint activation and attenuated the formation of γH2AX foci at telomeres in AR-inactivated cells, suggesting that ATM inhibitor induces apoptosis in AR-inactivated cells by blocking the repair of damaged DNA at telomeres. Finally, colony formation assay revealed a dramatic decrease in the survival of cells co-treated with Casodex and ATM inhibitor as compared with those treated with either Casodex or ATM inhibitor alone. These observations indicate that inhibitors of DDR signaling pathways may offer a unique opportunity to enhance the potency of AR-targeted therapies for the treatment of androgen-sensitive as well as castration-resistant prostate cancer." @default.
• W1772185780 created "2016-06-24" @default.
• W1772185780 creator A5020408355 @default.
• W1772185780 creator A5024556156 @default.
• W1772185780 creator A5046280416 @default.
• W1772185780 creator A5060933693 @default.
• W1772185780 creator A5068470636 @default.
• W1772185780 creator A5070026145 @default.
• W1772185780 creator A5084693085 @default.
• W1772185780 creator A5090124731 @default.
• W1772185780 date "2015-10-01" @default.
• W1772185780 modified "2023-10-16" @default.
• W1772185780 title "ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction" @default.
• W1772185780 cites W1553367038 @default.
• W1772185780 cites W1882606371 @default.
• W1772185780 cites W1964296201 @default.
• W1772185780 cites W1970891016 @default.
• W1772185780 cites W1972655555 @default.
• W1772185780 cites W1976385056 @default.
• W1772185780 cites W1982199027 @default.
• W1772185780 cites W1983829317 @default.
• W1772185780 cites W1985466390 @default.
• W1772185780 cites W1987322786 @default.
• W1772185780 cites W1991293489 @default.
• W1772185780 cites W2005658600 @default.
• W1772185780 cites W2014588353 @default.
• W1772185780 cites W2016011119 @default.
• W1772185780 cites W2018369441 @default.
• W1772185780 cites W2022811243 @default.
• W1772185780 cites W2027931017 @default.
• W1772185780 cites W2035389897 @default.
• W1772185780 cites W2046011405 @default.
• W1772185780 cites W2048037525 @default.
• W1772185780 cites W2050302428 @default.
• W1772185780 cites W2053300345 @default.
• W1772185780 cites W2059286602 @default.
• W1772185780 cites W2062284662 @default.
• W1772185780 cites W2064293531 @default.
• W1772185780 cites W2068359474 @default.
• W1772185780 cites W2074422164 @default.
• W1772185780 cites W2084960769 @default.
• W1772185780 cites W2087688041 @default.
• W1772185780 cites W2105117997 @default.
• W1772185780 cites W2107208323 @default.
• W1772185780 cites W2107633226 @default.
• W1772185780 cites W2114697209 @default.
• W1772185780 cites W2118498123 @default.
• W1772185780 cites W2119504728 @default.
• W1772185780 cites W2120757357 @default.
• W1772185780 cites W2123258564 @default.
• W1772185780 cites W2123295754 @default.
• W1772185780 cites W2125724353 @default.
• W1772185780 cites W2127014693 @default.
• W1772185780 cites W2129031151 @default.
• W1772185780 cites W2132899449 @default.
• W1772185780 cites W2149718327 @default.
• W1772185780 cites W2149938795 @default.
• W1772185780 cites W2150490516 @default.
• W1772185780 cites W2156391988 @default.
• W1772185780 cites W2158820560 @default.
• W1772185780 cites W2159261007 @default.
• W1772185780 cites W2161232591 @default.
• W1772185780 cites W2768923159 @default.
• W1772185780 doi "https://doi.org/10.1074/jbc.m115.671404" @default.
• W1772185780 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4646198" @default.
• W1772185780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26336104" @default.
• W1772185780 hasPublicationYear "2015" @default.
• W1772185780 type Work @default.
• W1772185780 sameAs 1772185780 @default.
• W1772185780 citedByCount "23" @default.
• W1772185780 countsByYear W17721857802016 @default.
• W1772185780 countsByYear W17721857802017 @default.
• W1772185780 countsByYear W17721857802019 @default.
• W1772185780 countsByYear W17721857802020 @default.
• W1772185780 countsByYear W17721857802022 @default.
• W1772185780 countsByYear W17721857802023 @default.
• W1772185780 crossrefType "journal-article" @default.
• W1772185780 hasAuthorship W1772185780A5020408355 @default.
• W1772185780 hasAuthorship W1772185780A5024556156 @default.
• W1772185780 hasAuthorship W1772185780A5046280416 @default.
• W1772185780 hasAuthorship W1772185780A5060933693 @default.
• W1772185780 hasAuthorship W1772185780A5068470636 @default.
• W1772185780 hasAuthorship W1772185780A5070026145 @default.
• W1772185780 hasAuthorship W1772185780A5084693085 @default.
• W1772185780 hasAuthorship W1772185780A5090124731 @default.
• W1772185780 hasBestOaLocation W17721857801 @default.
• W1772185780 hasConcept C105696609 @default.
• W1772185780 hasConcept C11960822 @default.
• W1772185780 hasConcept C121608353 @default.
• W1772185780 hasConcept C134935766 @default.
• W1772185780 hasConcept C143425029 @default.
• W1772185780 hasConcept C177336024 @default.
• W1772185780 hasConcept C185592680 @default.
• W1772185780 hasConcept C190283241 @default.
• W1772185780 hasConcept C2780192828 @default.
• W1772185780 hasConcept C29537977 @default.
• W1772185780 hasConcept C502942594 @default.
• W1772185780 hasConcept C54355233 @default.

• next